Literature DB >> 17525092

Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment.

Kenji Hirano1, Minoru Tada, Hiroyuki Isayama, Hiroshi Yagioka, Takashi Sasaki, Hirofumi Kogure, Yousuke Nakai, Naoki Sasahira, Takeshi Tsujino, Haruhiko Yoshida, Takao Kawabe, Masao Omata.   

Abstract

OBJECTIVES: Autoimmune pancreatitis (AIP) is a unique form of chronic pancreatitis, and has a favourable response to corticosteroid treatment (CST). Little is known, however, about the long-term outcome of AIP. This study aimed to document the prognosis without and with CST, and to examine the indication for CST. PATIENTS AND METHODS: The prognosis and clinical features of 23 patients without CST and 19 patients treated with CST from onset were investigated. In addition, factors concerning the late occurrence of unfavourable events related to AIP were examined.
RESULTS: The patients without CST were 19 men and four women, with an average age of 66 years. After an average observation period of 25 months, 16 patients (70%) developed unfavourable events including obstructive jaundice as a result of distal bile duct stenosis in four, growing pseudocyst in one, sclerogenic changes of extrapancreatic bile duct in nine, hydronephrosis as a result of retroperitoneal fibrosis in one, and interstitial nephritis in one. Patients with obstructive jaundice at onset showed a higher cumulative event occurrence rate (p = 0.025). The patients treated with CST were 16 men and three women, with an average age of 64 years. After an average observation period of 23 months, six patients (32%) developed unfavourable events consisting of interstitial pneumonia in three, and a recurrence of obstructive jaundice in three. In multivariate analysis, CST (HR 0.33, 95% CI 0.12-0.89, p = 0.029) and obstructive jaundice at onset (HR 3.09, 95% CI 1.14-8.32, p = 0.026) were significant predictive factors for unfavourable events.
CONCLUSION: CST could reduce AIP-related unfavourable events. The early introduction of CST is recommended especially for patients with obstructive jaundice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525092      PMCID: PMC2095691          DOI: 10.1136/gut.2006.115246

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

Review 1.  Recent concept of autoimmune-related pancreatitis.

Authors:  K Okazaki; K Uchida; T Chiba
Journal:  J Gastroenterol       Date:  2001-05       Impact factor: 7.527

Review 2.  Autoimmune related pancreatitis.

Authors:  K Okazaki; T Chiba
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

3.  Close relationship between autoimmune pancreatitis and multifocal fibrosclerosis.

Authors:  T Kamisawa; N Funata; Y Hayashi; K Tsuruta; A Okamoto; K Amemiya; N Egawa; H Nakajima
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

4.  Interstitial pneumonia associated with autoimmune pancreatitis.

Authors:  T Taniguchi; M Ko; S Seko; O Nishida; F Inoue; H Kobayashi; T Saiga; M Okamoto; T Fukuse
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

5.  Anti-carbonic anhydrase II antibody in autoimmune pancreatitis and tubulointerstitial nephritis.

Authors:  Hiroshi Nishi; Akihiro Tojo; Maristela Lika Onozato; Rika Jimbo; Masaomi Nangaku; Hiroshi Uozaki; Kenji Hirano; Hiroyuki Isayama; Masao Omata; Shinya Kaname; Toshiro Fujita
Journal:  Nephrol Dial Transplant       Date:  2006-11-30       Impact factor: 5.992

6.  High serum IgG4 concentrations in patients with sclerosing pancreatitis.

Authors:  H Hamano; S Kawa; A Horiuchi; H Unno; N Furuya; T Akamatsu; M Fukushima; T Nikaido; K Nakayama; N Usuda; K Kiyosawa
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

7.  Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis.

Authors:  Hideaki Hamano; Shigeyuki Kawa; Yasuhide Ochi; Hiroshi Unno; Nobuhiko Shiba; Masahisa Wajiki; Koh Nakazawa; Hisashi Shimojo; Kendo Kiyosawa
Journal:  Lancet       Date:  2002-04-20       Impact factor: 79.321

8.  Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy.

Authors:  Terumi Kamisawa; Naoto Egawa; Shigeko Inokuma; Kouji Tsuruta; Atsutake Okamoto; Noriko Kamata; Teruo Nakamura; Masakatsu Matsukawa
Journal:  Pancreas       Date:  2003-10       Impact factor: 3.327

9.  Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases.

Authors:  Kenji Notohara; Lawrence J Burgart; Dhiraj Yadav; Suresh Chari; Thomas C Smyrk
Journal:  Am J Surg Pathol       Date:  2003-08       Impact factor: 6.394

10.  Involvement of the biliary system in autoimmune pancreatitis: a follow-up study.

Authors:  Kenji Hirano; Yasushi Shiratori; Yutaka Komatsu; Natsuyo Yamamoto; Naoki Sasahira; Nobuo Toda; Hiroyuki Isayama; Minoru Tada; Takeshi Tsujino; Ryo Nakata; Tateo Kawase; Tetsuo Katamoto; Takao Kawabe; Masao Omata
Journal:  Clin Gastroenterol Hepatol       Date:  2003-11       Impact factor: 11.382

View more
  62 in total

1.  Radiological features of IgG4-related disease in the head, neck, and brain.

Authors:  Masaki Katsura; Harushi Mori; Akira Kunimatsu; Hiroki Sasaki; Osamu Abe; Toru Machida; Kuni Ohtomo
Journal:  Neuroradiology       Date:  2012-02-23       Impact factor: 2.804

2.  IgG4-related inflammatory pseudotumor of the trigeminal nerve: another component of IgG4-related sclerosing disease?

Authors:  M Katsura; A Morita; H Horiuchi; K Ohtomo; T Machida
Journal:  AJNR Am J Neuroradiol       Date:  2010-09-23       Impact factor: 3.825

3.  The therapeutic strategy for autoimmune pancreatitis is subject to the endoscopic features of the duodenal papilla.

Authors:  Kensuke Kubota; Atushi Nakajima
Journal:  Therap Adv Gastroenterol       Date:  2010-11       Impact factor: 4.409

4.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

Review 5.  Optimising corticosteroid treatment for autoimmune pancreatitis.

Authors:  Amaar Ghazale; Suresh T Chari
Journal:  Gut       Date:  2007-12       Impact factor: 23.059

6.  Retrospective study of steroid therapy for patients with autoimmune pancreatitis in a Chinese population.

Authors:  Bin Liu; Jing Li; Lu-Nan Yan; Hao-Ran Sun; Tong Liu; Zhi-Xiang Zhang
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

Review 7.  Diagnosis of IgG4-related sclerosing cholangitis.

Authors:  Takahiro Nakazawa; Itaru Naitoh; Kazuki Hayashi; Katsuyuki Miyabe; Shuya Simizu; Takashi Joh
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 8.  Retroperitoneal fibrosis associated with immunoglobulin G4-related disease.

Authors:  Nao Fujimori; Tetsuhide Ito; Hisato Igarashi; Takamasa Oono; Taichi Nakamura; Yusuke Niina; Masayuki Hijioka; Lingaku Lee; Masahiko Uchida; Ryoichi Takayanagi
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

9.  Autoimmune Pancreatitis.

Authors:  Gyanprakash A Ketwaroo; Sunil Sheth
Journal:  Gastroenterol Rep       Date:  2013-04-04       Impact factor: 3.651

10.  [Autoimmune pancreatitis--treatment and pitfalls in diagnostics].

Authors:  S Rasch; V Phillip; G Weirich; I Esposito; J Gaa; R M Schmid; H Algül
Journal:  Internist (Berl)       Date:  2014-10       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.